key: cord-1001664-d0aokspl authors: Galiez, R. d. M.; Bomfim, L. M.; Mariani, D.; Leitao, I. d. C.; Castineiras, A. C. P.; Goncalves, C. C. A.; da Silva, B. O.; Cardoso, P. H.; Arruda, M. B.; Alvarez, P.; Akira, V.; Rodrigues, D. G. M.; Costa, L.; Ferreira Junior, O. C.; Castineiras, T. M. P. P.; Faffe, D. S.; TANURI, A. title: Evaluation of the Panbio™ COVID-19 Antigen Rapid Diagnostic Test in subjects infected with Omicron using different specimens date: 2022-03-21 journal: nan DOI: 10.1101/2022.03.19.22272637 sha: 2df97a53e9a2f5e542c600157100e284dc43e50a doc_id: 1001664 cord_uid: d0aokspl Community testing is a crucial tool for the early identification of SARS-CoV-2 infection and transmission control. The emergence of the highly mutated Omicron variant (B.1.1.259) raised concerns about its primary site of replication, impacting sample collection, and its detectability by rapid antigens tests. We tested the Antigen Rapid Diagnostic Test (Ag-RDT) performance using nasal, oral, and saliva specimens for COVID-19 diagnosis in 192 symptomatic individuals, using RT-qPCR from nasopharyngeal samples as control. Variant of Concern (VOC) investigation was determined by the 4Plex SARS-CoV-2 screening kit. SARS-CoV-2 positivity rate was 66.2%, with 99% of the positive samples showing an amplification profile consistent with that of the Omicron variant. Nasal Ag-RDT showed higher sensitivity (89%) than oral (12.6%) and saliva (22.1%) Ag-RDTs. Our data showed the good performance of the Ag-RDT in a pandemic scenario dominated by the Omicron VOC. Furthermore, our data also demonstrated that nasal specimens perform better than oral and saliva ones for Omicron Ag-RDT detection. Since the beginning of the COVID-19 pandemic, the World Health Organization has advised widespread testing to identify infected individuals and control the onward transmission of the virus [1, 2] . SARS-CoV-2 can spread quickly in the global population and new variants can emerge due to different selective pressures [3] . In fact, the prolonged circulation of the virus has resulted in the emergence of multiple variants in different countries during the COVID-19 pandemic. Some variants are of great interest to public health due to the critical mutations they carry in the Spike (S) protein. These mutations, named Variant of Concern (VOC), can change the binding of neutralizing antibodies as well as the affinity of S to the angiotensin-converting enzyme 2 (ACE2) receptor [4, 5] . Since June 2021, we have faced several global waves of VOCs, such as Alpha, Beta, Gamma, Delta, and more recently Omicron [5, 6] . The latest Omicron variant (B.1.1.259) replaced the Delta variant very quickly and recently dominated the pandemic worldwide [7] . Omicron is a highly mutated strain, including 50 mutations in its genome and at least 32 in the Spike protein. The following mutations are present in Omicron Spike protein (A67V, Δ69−70, T95I, G142D, Δ143-145, Δ211, L212I, insertion 214-EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F). All these variations could impact Omicron's ability to escape from monoclonal antibodies and from neutralizing antibodies elicited by COVID-19 vaccines [7, 8] . Indeed, studies have reported approximately 25-fold to 40-fold reductions in serum neutralizing activity compared to historical D614G-containing strains from individuals immunized with the Pfizer BNT162b2 and AstraZeneca AZD1222 vaccines [9] [10] [11] [12] [13] . RT-qPCR is considered the gold-standard test in COVID-19 diagnosis to detect the viral genetic material in different body fluids [14] . SARS-CoV-2 starts its replication in the upper respiratory compartment making the nasopharynx the most informative site for swab collection since it is rich in viral RNA and antigens [15] . However, nasal swabs have also shown good sensitivity [16] . Other locations and fluids can also be used in COVID-19 molecular tests such as oral or gingival swabs and even spit saliva. Whereas RT-qPCR plays an essential role in the detection of infected individuals, the Antigen Rapid Diagnostic Tests (Ag-RDT) arose as a tool to detect SARS-CoV-2 viral proteins in a faster and less expensive way [1] . Most Ag-RDTs use a monoclonal antibody directed against the Nucleocapsid (N) protein. Mutations in VOCs are frequently present at the S protein. However, they can also occur at non-structural and other structural proteins such as N or ORFs 3, 6, 7, and 8 [4, 5] . The major concern is that VOC-related mutations can disturb the binding of the N capture monoclonal antibodies and decrease the sensitivity of the test. Omicron has a unique mutation in N protein (P13L) and a deletion of two amino acids (ER) in positions 32-33 [6] . The impact of these N protein mutations in the binding of monoclonal antibodies responsible for the capture and development of the Ag-RDT is unknown. The other way VOCs can impact the Ag-RDT results is by changing the initial site of viral replication. Usually, swab specimens are collected from the nasopharynx or nasal cavity. If VOC viral is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2022. ; replication initiates in the oral cavity instead, before spreading to the nasopharynx and nasal cavity, the usually collected specimens could fail to detect the initial phase of infection. This fact was reported by Marais et al 2021 during the beginning of Omicron spread in South Africa [17] . In the present study, we explored the diagnostic performance of nasal and oral swabs as well as saliva in symptomatic patients infected with the Omicron variant. Our main aim was to evaluate the performance of Ag-RDT on different specimens (nasal, oral, and saliva) compared with RT-qPCR from the nasopharyngeal swab as the gold-standard. Our secondary aim was to analyze the persistence/disappearance of Ag-RDT positivity in the different specimens until the 7th day after a positive diagnosis by RT-qPCR. The present study was approved by the local ethics review committee from Clementino Fraga Filho University Hospital (CAAE: 30161620.0.0000.5257) and by the national ethical review board (CAAE: 30127020.0.0000.0068). All enrolled participants signed written informed consent. Subjects were over 18 years old and presented with mild COVID-19 suggestive symptoms -such as fever, cough, runny nose, sore throat, anosmia, ageusia, headache, diarrhea, and myalgia-for up to 7 days. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Samples included a nasal bilateral middle-turbinate swab, an oral swab, a saliva sample, and a nasopharyngeal swab. Nasal samples were collected according to the Panbio TM COVID-19 Ag Test Device instructions for use. Participants abstained from ingestion of food, drink, or chewing tobacco and gum for 30 minutes before oral sample collection. Participants coughed 3-5 times, covering their mouth with disposable tissue paper, prior to the operator swabbing the inside of both cheeks, above and below the tongue, on gums, and hard palate. Furthermore, participants spat in a sterile recipient to collect at least 1 mL of saliva, then 300 µL were transferred with a pipette to the Ag-RDT elution tube. After 5-10 minutes of rest, the operator collected a nasopharyngeal swab and immediately placed it in viral transport media (VTM). Nasal, oral, and saliva specimens were tested immediately following collection using the Panbio™ COVID-19 Ag Test Device (Abbott) according to the manufacturer's instructions. Tests were run and read by trained technicians on-site in the testing center, within 15 minutes. The leftover samples of the Panbio™ elution tubes (~120 µL) were stored at 4 o C and shipped to the laboratory for RT-qPCR within 4 hours. Viral RNA from the nasopharyngeal swab, as well as nasal, oral, and saliva leftover is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2022. ; VOC investigations were made on SARS-CoV-2 RT-qPCR positive samples using a 4Plex SARS-CoV-2 for VOC screening kit (Bio-Manguinhos, Brazil). TaqMan probes for the SARS-CoV-2 virus were used for detection by amplifying a target region in the N gene and screening samples with suggestive profiles for the different VOCs. VOC profiles were given by combining results obtained of the deletions (Del) S106, G107, and F108 in the ORF1a gene (NSP6) and Del. H69 and V70 in the Spike gene from the samples tested. Samples were considered positive when Ct values for SC2-N, Wt Del NSP6, and Wt Del 69, 70 were lower than 40. The data from the study was acquired using the KoBoCollect online/offline web-based form (Available at: https://www.kobotoolbox.org). The dataset was extracted on XLSForms and merged with the corresponding laboratory data. Ag-RDT sensitivity and specificity from different specimens were determined in relation to RT-qPCR. From January 14, 2022, to February 7, 2022, a total of 192 individuals were tested for SARS-CoV-2 by RT-qPCR and Panbio™ Ag-RDT tests simultaneously at the Center for COVID-19 diagnosis of the Federal University of Rio de Janeiro. The SARS-CoV-2 positivity rate in our cohort was higher using RT-qPCR from nasopharyngeal swabs (66.2%) than Ag-RDTs. Nasal specimens yielded the highest is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.19.22272637 doi: medRxiv preprint positivity rate among the different Ag-RDTs (58.9%) compared with oral (8.6%) and saliva (14.6%) ( Table 1 ). The performance of Ag-RDT was higher when using nasal specimens than oral or saliva specimens, yielding 89% sensitivity compared with 12.6% and 22.1%, respectively. The specificity of Ag-RDT was 100% regardless of the specimen tested (Table 2) . When we analyzed the concordance among RT-qPCR and Ag-RDT results from different specimens, nine possible results were obtained (Figure 1 Table 1 ). Thirty-two individuals with a positive SARS-CoV-2 RT-qPCR result had a second visit within 7 days, when Ag-RDT from nasal, oral, and saliva specimens were tested again, as well as the RT-qPCR from nasopharyngeal swabs (Figure 3 ). At the second visit, the positivity rate of RT-qPCR fell to 78.1% (25/32), while the positivity rate of Ag-RDT from nasal specimens fell to 31% (10/32), and to 3% for Ag-RDT from oral or saliva specimens ( Figure 3 ). Figure 4 shows the concordance among RT-qPCR and Ag-RDTs results during initial and follow-up visits. The positive result observed with Ag-RDT from nasal specimens persisted longer than those detected from oral or saliva specimens. In fact, only nasal Ag-RDT maintained any concordance with RT-qPCR result at the second visit, although significantly lower than that observed at visit 1 (Figure 4) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint [18, 19] . It has been previously shown to perform well against SARS-CoV-2 VOCs such as Alfa, Beta, Gamma, and Delta that circulated earlier during the SARS-CoV-2 pandemic [20] . Omicron variant has 50 novel genomic mutations, of which 20 are in the S gene that encodes the Spike protein [22] . Omicron has a higher affinity for human ACE2 receptors compared with the Delta variant, indicating a higher potential for transmission [23, 24] . Initial studies showed that infection by the Omicron variant produced less severe disease and significantly reduced the odds of hospital admission compared with earlier variants, such as Delta [25, 26] . However, the onset of Omicron circulation raised concerns about Panbio TM COVID-19 Ag RDT performance against this VOC as it incorporated mutations and deletions in the N protein that could potentially affect antigen binding. There is also the possibility of the Omicron VOC modifying its cell tropism and infection kinetics, thus altering the site of viral replication throughout the disease course, thereby changing the appropriate specimen to collect for acute-phase diagnosis [8] [9] [10] [11] [12] . A study by Michelena et al., using nasopharyngeal samples (confirmed as Omicron variants by sequencing), showed that the Panbio™ COVID-I9 Ag Rapid Test Device had high sensitivity: 95.6% (Ct ≤20), 92.6% (Ct ≤25), 87.2% (Ct ≤30) and 81.8% (Ct ≤35) compared with nasopharyngeal RT-PCR, with a specificity of 100% [27] . In another study, Deerain et al. evaluated the analytical sensitivity of lateral flow devices against the SARS-CoV-2 Omicron variant using isolates cultured from clinical samples, and demonstrated that the Panbio TM COVID-I9 Ag Rapid Test Device consistently detected a sample (4/4 replicates or 100%) at a concentration of 6.39 log 10 copies/mL, corresponding to a Ct value of 25.8, underlining the high sensitivity of the test device [28] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint A previous report suggested that there are different replication sites for the Omicron VOC in the initial phase of infection, leading to earlier detection in oral or saliva specimens compared with nasal ones [17] . In our study, we examined the sensitivity and specificity of the Panbio TM COVID-19 Ag-RDT in 192 symptomatic individuals up to 7 days after symptom onset, using different specimens including nasal bilateral middle-turbinate swabs, oral swabs, and saliva samples, compared with the gold standard RT-qPCR. The Panbio TM COVID-19 Ag-RDT showed good performance for Omicron detection when using nasal specimens, with 89% sensitivity and 100% specificity. However, oral and saliva specimens performed poorly, with only 12.6% and 22.1% sensitivity, respectively. It is noteworthy that Ag-RDT from oral or saliva specimens alone did not detect any patient with a positive SARS-CoV-2-RT-qPCR result, no matter how early they were tested after symptom onset. RT-qPCR from nasopharyngeal samples and nasal Ag-RDT detected positive cases as soon as 0-1 days after symptom onset. Our data is in contrast with those reported by Marais 2021 [17] , but support previous observations using the Panbio TM COVID-19 Ag RDT for other VOCs detection [29] . On the other hand, Lin 2022 reported no difference between nasal and saliva specimens for Omicron diagnosis [30] . The discrepancy could potentially reflect our patient cohort, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.19.22272637 doi: medRxiv preprint corroborated the better performance of nasal specimens with Ag-RDT than oral or saliva speciemens, supporting the finding that the nasal speciemen is the best specimen type for acute COVID-19 diagnosis using the Panbio TM COVID-19 Ag RDT. These results are consistent with the manufacturer's instructions that require the use of nasal or nasopharyngeal swab samples with the Panbio TM COVID-19 Ag RDT [18, 19] . Studies using alternate specimen types such as oral swabs or saliva samples, which are not recommended in the product Instructions for Use, have produced lower sensitivity with the Panbio TM COVID-19 Ag RDT [32, 33] . To determine the genotype of SARS-CoV-2 infecting our patient cohort, we used VOC RT-qPCR assay that tests two deletions (Del: S106, G107 and F108; in the ORF1a gene NSP6 and Del: H69 and V70 in the Spike gene) in SARS-CoV-2 genome. The results showed that 96 of the 97 tested specimens (99%) were infected with the Omicron VOC, confirming previous sequence studies in our laboratory showing complete replacement of the Delta VOC by Omicron in the community prior to sample collection for this study. In conclusion, results from the present study demonstrated that Panbio TM COVID-19 Ag-RDT test performance is unaffected in vaccinated individuals infected with the Omicron VOC. Furthermore, the study demonstrated that nasal specimens are the optimal specimen type for Panbio TM COVID-19 Ag-RDT performance compared with oral and saliva specimens. The VOC RT-qPCR results are presented in Supplemental Table 1 . Antigen-detection in the diagnosis of SARS-CoV-2 infection. Interim guidance SARS-CoV-2 testing for public health use: core principles and considerations for defined use settings World Health Organization, WHO. 2021b. Tracking SARS-CoV-2 variants Novel SARS-CoV-2 variants: the pandemics within the pandemic SARS-CoV-2 Variant Classifications and Definitions Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Abdel-Moneim AS. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies Omicron likely to weaken COVID vaccine protection Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development Saliva swabs are the preferred sample for Omicron detection. medRxiv Ag (Nasal) Instructions For Use Panbio TM COVID-19 Ag (Nasopharyngeal) Instructions For Use Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study Omicron severity: milder but not mild Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2 Omicron Variant Where is Omicron? Comparison o SARS-CoV-2 RT-PCR and Antigen Test Sensitivity at Commonly Sampled Anatomic Sites Over the Course of Disease UFRJ COVID-19 Working group. Performance of an alternative RT-PCR procedure using residual sample from the Panbio™ Ag COVID-19 test Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant Investigating sensitivity of nasal or throat (ISNOT): A combination of both swabs increases sensitivity of SARS-CoV-2 rapid antigen tests We would like to thank the entire technical and administrative staff from LVM-IB and CTD-COVID-19/UFRJ for their invaluable support, making this and other studies by our group feasible. The authors declare that there is no conflict of interest to disclose.